University of Cincinnati researchers used cryogenic electron microscopy to visualize for the first time the ADAM17 enzyme bound to its regulator iRhom2, key to inflammatory signaling linked to conditions like rheumatoid arthritis and cancer. The study, published in PNAS, elucidates regulatory elements of ADAM17 activity, potentially paving the way for therapeutics with fewer side effects compared to current treatments.